Ozemback
Compounds

Peptides compound by compound: BPC-157, TB-500, KPV, MOTS-c and the rest

A reference desk, organised by molecule. For each compound: what it is, what has actually been measured, where it sits legally, and what is still unknown. We do not publish dosing and we do not publish protocols, because we are a publication and not your clinician.

Every site that ranks for these compounds sells something. That is the gap this desk exists to fill.

Compound files: status, evidence and dose, sourced
BPC-157No FDA approval. Recommended for compounding 8-6-1 in July 2026. No published human RCT. No approved dose. SermorelinFormerly FDA approved as Geref, for children and diagnosis only. Discontinued 2008, not for safety. Never approved for adults. TesamorelinFDA approved since 2010 for HIV-associated lipodystrophy only. Label says not for weight loss. Not named on the 503A bulks page. GestrinoneNot FDA approved. A steroid, not a peptide, and NOT part of the July 2026 vote. All the safety data is from 3,745 women treated for endometriosis. TB-500No FDA approval. Not on the 503A list. Committee voted 8-6 in favour in July 2026, against FDA staff. FDA found no human study. SemaxNo FDA approval. Registered in Russia as nasal drops. Committee voted 8-5 in favour in July 2026, against FDA staff. No human PK study. EpitalonNo FDA approval. Committee voted 7-4 in favour for insomnia in July 2026, against FDA staff. FDA found no clinical safety data. MOTS-cNo FDA approval. Committee voted 7-5 in favour in July 2026, against FDA staff. FDA found no study of it in humans by any route. KPVNo FDA approval. Committee voted 8-6 in favour in July 2026, against FDA staff. HHS draft policy covers topical and oral forms only. No human study. GHK-CuNo FDA approval. Back under FDA evaluation since May 2026 for non-injectable routes only; injectable GHK-Cu was flagged in Category 2. Not in the HHS draft policy. Emideltide (DSIP)No FDA approval. The only peptide the committee voted down in July 2026, 6-7-1. Not in the HHS draft policy. Every human study was intravenous. IpamorelinNo FDA approval. An FDA committee voted against it on 29 October 2024, 0-12-1. 503B Category 2. Not part of the 2026 peptide review. Every human trial was intravenous.
5 articles in this desk
Ozemback is independent journalism. Nothing on this site is medical advice. Nothing replaces a licensed clinician. Read the disclaimer